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Chronic heart failure (HF) imposes a large public health burden in terms of morbidity, mortality, and economic cost. HF with reduced left ventricular ejection fraction (LVEF) is associated with a hypercoagulable state, formation of left ventricular thrombus, cerebral embolism, and death from atherothrombotic events [1] . As such, anticoagulation is recommended for HF patients with atrial fibrillation (AF), and considered for those without AF but with previous embolic events [2] .
Warfarin, the current mainstay of anticoagulation in HF, requires frequent monitoring and dosing adjustment, and is thus difficult to manage. This difficulty is concerning given that poor warfarin control is associated with increased risk of death, myocardial infarction, and stroke [3] . Further, as most HF patients have reduced heart failure-related quality of life (HFQoL) [4] , a characteristic that has been associated with medication non-adherence in other patient populations [5] , treatment with warfarin may present even greater challenges in this population.
Although some studies have examined patient factors that predict anticoagulant control [6] , the effect of HFQoL-a potentially modifiable factor-on anticoagulant control in HF has never been investigated.
In this ancillary analysis of 1,142 participants from the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, we tested whether reduced HFQoL was independently associated with poor warfarin control.
Details of the WARCEF trial have previously been published [1] . Briefly, patients who were 18 years of age or older and had HF in normal sinus rhythm, no contraindication to warfarin, and a LVEF < 35% or wall-motion index ≤ 1.2 were randomized to receive either warfarin or aspirin therapy. Additional eligibility criteria included a modified Rankin score ≤ 4
and planned treatment with a beta-blocker, angiotensin-converting-enzyme inhibitor, or M A N U S C R I P T
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Warfarin and Quality of Life 3 hydralazine and nitrates. Patients randomized to receive warfarin were managed by local practice guidelines with at least monthly international normalized ratio (INR) testing.
For this study, we included 1,142 participants randomized to warfarin therapy with targeted INR between 2.0 and 3.5. The trial was performed in 168 centers from 11 countries around the world. All local institutional review committees approved the study protocol, and all patients provided informed consent for trial entry.
A modified time in therapeutic range (TTR) metric was calculated to estimate warfarin control [7] . The median TTR was 63% (interquartile range, 39%). Participants whose TTR was
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Warfarin and Quality of Life 4 below the median were younger, and less likely to be White, non-Hispanic than those with TTR was above the median ( Table 1) . These participants were also more likely to have had hypertension and ischemic stroke.
In an age-and sex-adjusted regression model ( Table 2) Additionally, having a recent stroke was associated with a 42% decrease in the odds of being in therapeutic range (p = 0.01), and White, non-Hispanic race/ethnicity was associated with a 74% increase in the odds (p < 0.001) of being in therapeutic range.
In this large cohort of 1,142 patients with HF, we examined for the first time whether
HFQoL is associated with warfarin control, and found that reduced HFQoL was independently associated with reduced odds of being in therapeutic range. Although a previous study found no association of quality of life with anticoagulation control, that study was limited by a small sample of 52 non-HF patients, a cross-sectional design, and a non-validated measure of quality of life [10] . Consistent with previous literature [9], however, we observed associations of White, non-Hispanic race/ethnicity with greater odds and recent stroke with reduced odds of being in therapeutic range. Given that those with recent stroke have a high recurrent stroke rate, special attention needs to be placed on effective anticoagulant control in this population. Apostolakis and colleagues recently derived a prediction model for anticoagulant control that included both race/ethnicity and stroke (among other medical comorbidities); however, this model did not include HFQoL, and thus the incremental value of adding this parameter to their model may be
Warfarin and Quality of Life 5 worth examining. Further, although age independently predicted TTR in their model as well as in our minimally-adjusted prediction model, its predictive value was attenuated to non-significance in our fully-adjusted model. This curious finding may reflect limited statistical power or a confounding or mediating effect of other covariates on the age-TTR association-scenarios that could be tested in future studies.
Of note, we did not assess all potential patient characteristics known to interfere with anticoagulant therapy. In addition, we did not include a measure of medication adherence to test whether this factor partially explains the association of HFQoL with warfarin control.
In conclusion, we found that reduced HFQoL is associated with reduced warfarin control among HF patients with reduced LVEF in normal sinus rhythm. Future research could consider whether intervening to improve HFQoL has beneficial downstream effects on TTR or whether newer anticoagulants that do not require frequent dosing adjustments on the basis of a TTR have a role in the management of HF patients with poor HFQoL who require systemic anticoagulation.
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